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In prostate cancer, an interesting and intriguing option to overcome the risks of whole-gland treatment is focal therapy, with the
aim of eradicating known cancer foci and reducing collateral damages to the structures essential for maintaining normal urinary
andsexualfunction.Ablationofallknownlesionswouldfavorablyalterthenaturalhistoryofthecancerwithoutimpactinghealth-
related quality of life and allows for safe retreatment with repeated focal therapy or whole-gland approaches if necessary. Our
objective is to reassess the possibilities and criticisms of such procedure: the rationale for focal therapy and the enthusiasm come
from the success of conservative approaches in treating other malignancies and in the high incidence of overtreatment introduced
by prostate cancer screening programs. One of the challenges in applying such an approach to the treatment of prostate cancer is
the multifocal nature of the disease and current diﬃculties in accurate tumor mapmaking.
1.Introduction
Prostate cancer PC remains the most common, noncuta-
neousmale malignancy, with an estimated 186,320new cases
diagnosed in2008in theUnitedStates[1].Si m i la rﬁ gur esa r e
reported in Europe: PC is the most common solid neoplasm,
with an incidence of 214 cases per 1000 men [2]. With
current trends of PSA testing, and the lowered PSA threshold
for biopsy in some Western countries, more and more men
will be diagnosed with PC. Although autopsy studiesshowed
that cancer cells can be found in the prostate of 30% to 40%
of men at age 60 years (and 60% to 70% at 80 years), the
lifetime risk of clinically signiﬁcant and fatal prostate cancer
of a 50-year-old man was estimated to be 9.5% and 2.9%,
respectively [3].
Recently,thecontroversyonthebeneﬁt ofPSAscreening,
as well as the known side eﬀects of screening itself, served to
highlight the concerns about overdetection and consequent
overtreatment of patients who fall in the category of the so-
called low-risk prostate cancer [4–6].
Current treatment of choice for men with localized
prostate cancer lies between active surveillance and radical
therapy.Therationaleofactivesurveillanceforlow-risk,low-
stage prostate cancer is sound; however, undertreatment is
an inherent risk of active surveillance. Nearly one-fourth to
one-third of patients, who are thought to be ideal candidates
for a policy of no treatment, is later recommended to have
therapy once additional information is obtained [7, 8]. In
addition, active surveillance,being a “do-nothing”approach,
carries the psychological burden of allowing a known cancer
to adversely aﬀect quality of life.
Radical prostatectomy is eﬀective; however, because of
the risks of postoperative complications (urinary and sexual
dysfunction, as great with robotic-assisted prostatectomy as
with any other technique [9]), patients with low-risk cancer
mightbeattractedtomoreconservativealternatives(external
beam radiotherapy EBRT or brachytherapy BT). However,
they may carry the long-term risks of bowel, sexual, and
urinary dysfunction as well [10].
In the last two decades, there has been an awareness of
changing treatment paradigmsforothercancer: forexample,
the use of breast sparing surgery, that is, lumpectomy, to
treat breast cancer revolutionized the control of that disease:
to date, lumpectomy followed by radiation is likely to be
equallyaseﬀectiveasmastectomyinselectedpatients;patient
qualityof life can successfully be integrated into the equation
of cancer treatment without loss of treatment eﬃcacy
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Similarly, in urology, small renal lesions may be better
suited to partial rather than radical nephrectomy as there is a
beneﬁt to maintain as many nephrons as possible. Men with
prostate cancer face many of the same issues that breast or
kidney cancer patients do, and in recent years the concept of
a subtotal therapy has gained the interest of some urological
schools [12].
The new goal of future intervention in the treatment
of prostate cancer is the Trifecta concept [13]: it means
being cured, continent and potent; this is the mainstay of
minimally invasive therapy such as focal ablation.
Focal therapy can encompass any degree of subtotal
glandular ablation using a variety of devices or techniques
derived from experience of whole-gland treatment. Focal
therapy is being increasingly discussed as an intriguing
treatment option but several issues remain to be addressed.
The aim of this paper is to discuss pro and contra of
focal therapy of prostate cancer, presenting possibilities and
criticisms according to actual knowledge.
2.Materialsand Methods
A literature search was done using MEDLINE/Cochrane
libraries from 1995 to 2009 using medical subject head-
ings “prostate cancer,” “male lumpectomy,” “focal therapy,”
“ablative,” “cryotherapy,” “HIFU,” “laser,” or “photodynamic
therapy.”
Original articles, review articles, and editorials published
in the years 1995–2009 were included and reviewed in order
to select relevant articles.
In November 2010, search for the role of focal therapy
or male lumpectomy in prostate cancer produced 492 and
18 references, respectively; searching for prostate cancer,
focal therapy, and cryotherapy produced 35 references, of
which 21 were reviews; searching for prostate cancer, focal
therapy, and HIFU produced 51 references, of which 21 were
reviews. Prostate cancer and focal therapy and laser therapy
or photodynamic therapy produced 19 and 14 references,
respectively (4 and 8 reviews, resp.).
A r g u m e n t si nf a v o u ro fo rc r i t i c i s m st of o c a lt h e r a p ya r e
discussed and presented together with preliminary experien-
ces.
3.Discussion
3.1. Pros
3.1.1. Improvement in Detection of Focal Prostate Cancer. In
the PSA screened era, prostate cancer as unilateral disease
has been shown to exist in 20–40% of men, whilst unifocal
disease may be present in up to 70% of men with newly
diagnosed localized prostate cancer [14–16]. The Cancer
of the Prostate Strategic Urologic Research Endeavor [17]
showed that the proportion of patients with unilateral,
low-volume tumors with low-risk clinical and pathologic
characteristics rose from 29.8% in 1989–1992 to 45.3% in
1999–2001. Polascik et al. [18] showed that among patients
with T2 disease, there was a notable increase throughout
the years in the proportion of unilateral, low-volume (pT2a)
tumors, from 10% in 1988–1995 to 69.4% in 2001–2006.
Noguchi et al. [19] demonstrated that the presence of
secondary cancers in multifocal prostate tumors did not
predict subsequent clinical behavior.
A strong argument against focal therapy is the fact that
the majority of men with clinically localized prostate cancer
has multifocal disease; however, multifocality included a
large proportion of small tumours which may represent
clinically insigniﬁcant (indolent) disease that are unlikely to
progress and impact on quantity of life. 80% of tumour foci
has a volume <0.5cc[20] and may represent inconsequential
disease overa10–15yearperiod,while allotherlesionsabove
0.5 cc tend to harbour more aggressive disease (higher grade
and stage). Furthermore, there are also evidence that there
is usually only one clinically signiﬁcant clone in the prostate
beingresponsibleformetastases,andthisistheonlyclinically
signiﬁcant lesion[21]:ablationofthedominantlesion(s)will
give rise to disease control [22].
Template transperineal biopsies can serve the purpose
to detect the so-called index lesion [23], and it has been
accepted as the standard for evaluating patients’ eligibility
in trials of focal therapy. Crawford et al. [24]r e p o r t e d
a 95% accuracy using a perineal brachytherapy template.
Similar results were found by Furuno, who found 87%
accuracy in comparison with surgical data [25]. Accuracy of
prostate mapping with conventional endorectal MRI shows
sensitivity up to 85%; the new multiparametric imaging
(dynamic contrast-enhanced MRI, diﬀusion-weighted MRI,
and MR spectroscopic imaging [26]) are considered the best
imaging for identiﬁcation and staging of cancer [27–29].
Modern biopsy strategies, combined with optimal imaging
and nomograms, provide a strong basis for the inclusion of
patients into prospective clinical trials of focal therapy [30].
3.1.2. Avoiding Overtreatment of Low-Risk Prostate Cancer.
The European Screening study showed that 1410 men
need to be screened and 48 diagnosed in order that one
prostatecancer-related deathisavoidedovera 9-yearinterval
[5]: in this view, some patients are over-treated, and this
overtreatment should not be a problem if solution is cost
eﬀective and associated with low toxicity.
The Scandinavian trial [31] comparing surgery versus
watchful waiting showed an absolute risk reduction by sur-
gery in preventingcancer mortality within 8years of 5%,and
a recent update showed that this diﬀerence did not change at
longer followup. However, this diﬀerence is probably smaller
in a PSA-screened population, since lower-risk disease is
detected earlier [32]. The advantage of radical therapy may
also become smaller if watchful waiting is substituted with
active surveillance which, however, is characterized by a
significant dropout [33]. Focal therapy lies between the un-
dertreatment of active surveillance and the overtreatment of
radical approaches.
3.1.3. Reduction of Side Eﬀects of Whole Gland Therapy. It
is widely demonstrated that radical whole-gland therapy is
associated with signiﬁcant side eﬀects.Prostate Cancer 3
Despite improvements in surgical techniques, urinary
incontinence UI is not uncommon after radical prostatec-
tomy (RP) [34]: the rate of early UI (3–6 months) varied
from 0.8% to 87% and from 5% to 44.5% at 12 months
[35, 36]. Several predictors of postoperative UI have been
investigated, but unfortunately, they rarely reach a high level
of evidence [37]. UI after RP or radiotherapy is caused by
sphincter damage [38] and by bladder dysfunction, such
as detrusor overactivity and low compliance [39]. UI is a
particularly upsetting problem, and it dramatically worsens
quality of life QoL [40].
Surgery or radiotherapy causes erectile dysfunction ED
in 30–90% of men, with a lower incidence in high-volume
center [41]. Despite improvements in surgical techniques,
ED is not uncommon after radical prostatectomy [42, 43]:
several predictors have been investigated, but unfortunately,
they rarely reached a high level of evidence [44]. ED after
RP has been related to nerve damage (neuropraxia) resulting
in penile hypoxia, smooth muscle apoptosis, ﬁbrosis, and
venous-occlusive dysfunction [42], and it is a particularly
upsetting problem after RP, worsening quality of life [45].
Patients undergoing radiotherapy develop as well ED in up
to 75% of cases, even with the advent of the new protocol of
intensity modulated radiation therapy (IMRT) [46].
The best modality to optimizep o s t c a n c e re r e c t i l ed y s -
function management has not yet been standardized and is
still challenging [47–49].
Problems with bowel function rarely occur after RP
[50], while Widmark et al. showed that 59% of patients
undergoing radiotherapy reported gastrointestinal problems
compared with 14% of age-matched controls [51]. In
anotherstudy,25%reportedmoderateand11%severebowel
changes, including fecal soiling (5%) and bowel frequency
(4%) [52]. Another paper has reported greater rates of
fecal soiling (10%) and bowel frequency (7%) [53], which
can persist for many years. Potosky et al. noted that at 5-
year followup, men who had undergone EBRT were still
more likely to report bowel urgency and problems with
hemorrhoids than men who had undergone surgery [54].
Even brachytherapy has an impact on bowel function: a 3%
of rectal bleeding was reported [55], while in a study by
Talcottetal.,theincidenceofrectalurgencywas 14%and the
incidence of rectal bleeding 6% [56]; Krupski et al. reported
that the probability of experiencing problematic diarrhea
was 20% at 3 months, 15% at 6 months, and 12% at 9
months [57]. More recently, Miller et al. conﬁrmed that men
who underwent EBRT or BT had signiﬁcantly worse bowel
function than men who underwent surgery or age-matched
controls [58].
Focal therapy is diﬀerent from a whole gland treatment:
focal means to not target bladder, sphincter, neurovascular
bundles, and bowel and should spare continence, erectile
function, and overall quality of life.
3.1.4.Improving Overall Quality of Life. Allthestudiesfound
that changes in quality of life were signiﬁcantly related
to satisfaction with overall outcome among both patients
and their partners. Treatment-related changes in quality of
life among patients due to a whole gland therapy caused
distress in their partners. A multicenter trial showed that
a patient’s therapy had an eﬀect on the well-being of the
patient’s spouse or partner [59]: the level of spousal distress
arising from a patient’s sexual and urinary symptoms after
primary prostate-cancer treatment was also associated with
thepartner’slevelofsatisfactionwiththetreatmentoutcome.
These ﬁndings conﬁrm those of single-institution studies
suggesting that patients’ urinary or sexual symptoms are
problematic for their partners [60].
3.1.5. Cost Saving. Various global economic scenarios are
altering the landscape of whole gland therapy. In a random-
ized trial comparing RP versus watchful waiting WW, at a
median followup of 12 years, the overall cost in the RP group
was34%higherthanintheWWgroup[61].Inarecentcom-
parison of open RP versus laparoscopic LRP versus robotic
radical prostatectomy RALP, Bolenz et al. showed that RALP
is associated with higher cost [62]. Intensity-modulated
radiotherapy is more eﬀective but more expensive than con-
ventional radiotherapy [63]. It is possible that in the future
health care systems required more cost-eﬀective care ﬁnding
in focal ablation a cost-eﬀective therapy: eﬀectively, in a
comparative study between open RP, LRP, and cryoablation
ofprostate CAP, the overall direct costsof CAPwere oﬀset by
the signiﬁcantly lower nonoperative hospital costs [64].
In conclusion, the overall outcome of whole gland pros-
tate cancer treatment is sensitive to divergent changes in
quality of life of patients and their partners due to conti-
nence, sexual and bowel function, with increasing costs for
the health care system. Investigation on new organ sparing
technique [65–70] which could reduce the incidence of ad-
verse events and improve quality of life might represent a
valuable new strategy for management of PC.
3.2. Cons
3.2.1. Undertreatment of Signiﬁcant Prostate Cancer. The
contra of focal therapy lies in the undertreatment of patients
with clinically signiﬁcant disease. The major arguments
against focal therapy can be classiﬁed under the broad head-
ingof“understaging”andtheunderstagingargument centers
around the multifocality of prostate cancer: multiple foci are
found in the majority of specimens [71–73], while it would
appear that few patients have true unifocal disease [74]. Low
tumor volume is a favorable prognostic feature and predicts
low risk of metastasis; however, low tumor volume does not
guarantee unifocality. In low-volume disease, there might
be multifocal pattern at the same time, even if the size of
largest focus “index lesion” seems to determine the patient’s
prognosis. However, the independent role of Gleason grade
cannot be overlooked, and high-grade PC, even in low
volume or small foci, represents a risk if untreated.
The concept of treating only the index tumor in selected
men is based on a number of pathologic studies. Villers et
al. [75] showed that 80% of secondary tumors are <0.5mL;
Rukstalis et al. [76] found that the median size of ancillary
lesionswas0.3ccandproposedthat79%ofmenwouldlikely4 Prostate Cancer
have insigniﬁcant residual cancer if the index tumor was
ablated. However, although treatment of the index tumor
has been suggested, to date, there is no technology for
reliablediseasemapping;moreover,we lackdeﬁnedfollowup
protocols for the residual prostate that was not ablated and
whether the residual prostate would compromise long-term
disease control.
3.2.2. Ideal Candidate to Focal Therapy. The major obstacle
lies in proper identiﬁcation of the ideal patient for focal
therapy.Themostcommonmodality fordiagnosingprostate
cancer is prostate biopsy, which remains a poor predictor
of the extent of tumor on ﬁnal pathologic specimen: scales
found only a 35% positive predictive value of a unilateral
biopsy when compared with ﬁnal RP pathologic specimen
[15]; even a saturation biopsy fails to accurately identify the
presence of a unilateral tumour in the RP specimen [77]:
a mere 22.6% of patients with unilateral core involvement
on biopsy had conﬁrmed unilateral PC in the RP specimen,
and none of the routinely available clinical and pathological
characteristics was found to be an independent predictor of
unilateral tumour in the RP specimen.
The consequences of improperly designating a patient
for focal therapy may be profound. While the smaller non-
indexcancerrarelydeterminesprognosis,metastaticdeposits
have chromosomal alterations discordant with the largest
tumor in the prostate, suggesting that nonindex tumors can
metastasize [78].
3.2.3. Problems with Diagnostic Tools. Even though template
mapping biopsies provide the accuracy needed to administer
focal therapy, they have several limitations: there is a higher
risk of infection, and in rate of acute urinary retention,
extensive sampling increases the morbidity ofsubsequentRP
in patients unsuitable for focal therapy. Saturation biopsy
requires anesthesia, and, ﬁnally, the cost of the procedure is
another important factor to be taken into consideration.
Magnetic resonance imaging has been proposed as an
alternative imaging modality to guide prostate biopsy: in a
small series including patients with prior negative biopsy,
cancer was detected in 55.5% of patients undergoing MRI-
guided biopsy [79]; however, the yield of MRI-guided biopsy
is similar to repeat systematic TRUS-guided biopsy.
Primary reports for accuracy of endorectal MRI prostate
cancer staging show sensitivity up to 85%; however, one of
the limitations of MRI is the diﬃculty of diagnosing central
cancer, due to overlapping benign prostatic hyperplasia.
Additionally,menwhohavehadrecentbiopsiesoftenpresent
with hemorrhage, which limits MRI accuracy.
Nevertheless, tumor characterization and risk estimation
remain imperfect.
3.2.4.Deﬁnition ofCancer Control. The othermost problem-
atic area relates to the deﬁnition and timing of the surrogate
cancer-related outcomes used. Focal therapy will be prob-
lematic as some tissue is left untreated, and this inevitably
gives rise to PSA increasing. Deﬁnitions of biochemical
recurrence-freeprogressionarenotwellestablished:Lambert
et al. [80] use a deﬁnition of PSA nadir 50% from baseline
after unilateral cryotherapy. Longer followup and validation
through other mature series will be needed to deﬁne the role
of PSA and followup schemes. Absence of cancer in treated
lobe is characterized by the same bias of preoperative accu-
racy of prostate biopsy. The other unanswered question (at
least to date) is which retreatment is suitable in case of local
persistence or relapse; there are few studies in the literature
in the feasibility of radiotherapy, radical prostatectomy, or
repeating cryotherapy or HIFU.
3.2.5.FunctionalOutcomes. Lastly,apresumedbutunproven
advantageoffocaltherapyisthelowerlikelihoodandseverity
of treatment-related morbidity. While this is intuitive, it
must be conﬁrmed through trials: treatment-related side
eﬀects can be relatively well captured using validated ques-
tionnaires in order to compare focal therapy with standard
therapies. Questionnaires will be principally directed at gen-
itourinary associated outcomes and at global assessment of
quality of life; complication will be classiﬁed according the
Clavien-Dindo Classiﬁcation.
4.EarlyExperienceswithFocal Therapy
The technique of ablating part of the gland may, in practice,
represent the most achievable clinical approach. Focal ther-
apy can be delivered using a number of ablative modalities
that treats small, selected tissue, including cryosurgery, high-
intensity focused ultrasound HIFU, laser ablation, and pho-
todynamic therapy.
Current strategies for organ-preserving prostate cancer
ablative therapy have varied in their eligibility criteria and
in the amount of tissue targeted for destruction and/or
preservation:nerve-sparingprostateablation,hemi-ablation,
hockeystick,and targetfocaltherapy. Despitepaucityof data
and a lack of consensus on the most appropriate eligibility
and selection criteria, treatment template, and best method
of delivering thermal destruction, this approach has become
increasingly popular.
4.1. Cryosurgery. Preliminary clinical trials of focal cryo-
hemiablation suggest that it is feasible, with excellent cancer
control and minimal complications although the study
design and the scientiﬁc standard were poor [80–84]. Focal
cryotherapy is a promising option for carefully selected
patients although optimization of inclusion criteria is re-
quired,since selection criteria are associated with cancer-free
survival. Further followup will determine optimal patient
selection criteria and followup protocols for patients under-
going primary focal unilateral nerve-sparing prostate cancer
treatment. Erectile function is preserved in 68–93% of cases,
while no patients reported worsened lower urinary tract
symptoms, incontinence, rectal pain, perineal discomfort, or
ﬁstula formation [80, 81].
4.2. HIFU. HIFU is already being used (unfortunately out-
side of formal clinical trials), and the preliminary data areProstate Cancer 5
encouragingalthoughdiﬀerenteligibilitycriteriaandparam-
eters of treatment, short followup, and absence of patient-
reported outcomes make these results hard to interpret.
To date, focal therapy series had evaluated hemiabla-
tion of unilateral disease with a Gleason score ≤7, PSA
≤15ng/mL, clinical stage ≤T2b, using cryosurgery or HIFU.
Safety analysis of focal HIFU has demonstrated impotence
rates of approximately 15% with little to no incontinence
[85, 86].
4.3. Laser Ablation. Interstitial laser thermal focal therapy
experience is at the beginning, and clinicalreports are scarce:
in most cases, the literature discusses technical aspects of
laser delivery system [87, 88]o rP h a s eIt r i a l[ 89, 90], report-
ing interesting results in terms of erectile function sparing
and continence, while oncological data are inconsistent for
cases and followup.
4.4. Photodynamic Therapy. Photodynamic therapy shows
promise in delivering focal treatment of both primary and
postradiotherapy prostate cancer. Research is ongoing to
evaluatemechanism ofactionofphotodynamicenergydeliv-
ery, development of newer vascular-acting photosensitizers,
and potential advantages and disadvantages in focal therapy
[91].
5.Conclusion
Organ-sparing focal therapy may ﬁll the gap between an
active surveillance strategy and whole-gland treatmentpro-
viding a reasonable balance between cancer control and QoL
issues in the future [92].
Focal therapy is still in its infancy. Currently, we do have
the optimal basic technology and experience to carry out
focal therapy. Candidates for enrollment in trials of focal
therapy for localized prostate cancer should meet low-risk
criteria based on clinical biopsy and imaging data [79]; with
inappropriate patient selection, the potential for missing
curative opportunities exists.
The important next steps should be to use an evidence-
based approach to study the selection of ideal candidates and
subsequently deﬁne successful oncologic outcomes of focal
therapy. Deﬁnitions of success or failure and triggers for re-
treatment have not been established.
Early results with cryotherapy and HIFU appear encour-
aging, even if to date experience is limited and followup is
immature.
Feasibility studies for focal therapy of the prostate are
underway [93]. Attempting to set and meet guidelines for
oncologic eﬃcacy is a challenge we must embrace to safely
deliver this revolutionary approach to treating men with
prostate cancer.
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